Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19

Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of business on October 19, 2026 will receive, and have attached, one CVR. Each share issued after the record date and before any detachment of the CVRs or expiration of the CVR Agreement will also carry and have attached one CVR.

The CVRs will remain attached, or "stapled," to Atossa common stock unless and until the Board of Directors elects to detach them (for example, to permit CVRs to trade separately). While stapled, each CVR may be transferred only together with its corresponding share of common stock. Accordingly, when a share carrying a CVR is sold or otherwise transferred, the attached CVR will transfer with that share. While attached, the CVRs will not trade separately, have a separate CUSIP or be reported separately on brokerage statements.

The October 19 record date establishes the shares entitled to the initial CVR dividend; it does not detach the CVRs from those shares. Investors who subsequently acquire shares carrying an attached CVR will acquire the CVR together with the common stock.